SequelSEC

PULSE BIOSCIENCES, INC. PLSE

Surgical & Medical Instruments & Apparatus · CIK 0001625101 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$434.00K
Fiscal year ended 2026-06-30
Operating income
-$25.27M
Fiscal year ended 2026-06-30
Free cash flow
-$18.80M
Fiscal year ended 2026-06-30

PULSE BIOSCIENCES, INC. (PLSE) reported revenue of $434.00K and net income of -$24.66M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from PULSE BIOSCIENCES, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

PULSE BIOSCIENCES, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$434.00K$401.00K$264.00K$86.00K$0$0$0$0$0$0
Cost of revenue$273.00K$370.00K$260.00K$279.00K$0$0$0$0UnavailableUnavailable
Gross profit$161.00K$31.00K$4.00K-$193.00K$0$0$0$0UnavailableUnavailable
Operating income-$25.27M-$19.15M-$18.25M-$20.37M-$20.28M-$18.04M-$20.26M-$13.66M-$11.73M-$10.62M
Net income-$24.66M-$18.58M-$17.43M-$19.38M-$19.17M-$16.80M-$19.38M-$12.68M-$11.38M-$10.14M
Research & development$16.98M$12.59M$10.93M$11.39M$12.09M$10.31M$10.66M$7.70M$7.23M$6.74M
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailable-$19.17M-$16.80M$87.80M-$12.68M-$11.38M-$10.14M
Income tax expenseUnavailableUnavailableUnavailableUnavailable$0$0$0$0$0$0
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrative$8.46M$6.59M$7.33M$8.78M$8.19M$7.73M$9.60M$5.95MUnavailableUnavailable
General & administrativeUnavailableUnavailableUnavailableUnavailable$8.19M$7.73M$9.60M$5.95M$4.50M$3.87M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

PULSE BIOSCIENCES, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$101.62M$68.32M$80.74M$95.21M$106.35M$119.28M$118.04M$79.03M$26.20M$34.88M
Total assets$115.56M$81.62M$94.54M$108.76M$120.25M$133.38M$132.46M$93.05M$40.43M$49.16M
Current assets$105.70M$71.13M$83.42M$97.16M$108.16M$120.91M$119.45M$80.41M$27.24M$35.85M
Total liabilities$16.06M$15.32M$13.88M$16.07M$15.76M$14.93M$17.60M$13.92M$13.46M$12.88M
Current liabilities$10.98M$9.80M$7.92M$9.70M$8.98M$7.76M$10.06M$6.74M$5.96M$5.08M
Total equity incl. NCI$99.50M$66.30M$80.66M$92.69M$104.49M$118.45M$114.86M$79.13M$26.97M$36.29M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$236.00K$206.00K$136.00K$57.00K$51.00K$30.00K$0UnavailableUnavailableUnavailable
Accounts receivable$122.00K$157.00K$274.00K$15.00KUnavailableUnavailable$0UnavailableUnavailableUnavailable
Goodwill$2.79M$2.79M$2.79M$2.79M$2.79M$2.79M$2.79M$2.79M$2.79M$2.79M
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$2.83M$2.76M$2.78M$2.98M$2.74M$2.37M$1.67M$1.73M$1.64M$1.71M

Cash flow

PULSE BIOSCIENCES, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$18.71M-$14.60M-$14.76M-$13.04M-$12.81M-$13.52M-$9.14M-$9.02M-$8.40M-$9.78M
Capital expenditures$90.00K$33.00K$105.00K$62.00K$103.00K$45.00K$53.00K$38.00K$29.00K$5.00K
Investing cash flow-$90.00K-$33.00K-$105.00K-$62.00K-$123.00K-$45.00K-$53.00K-$38.00K-$29.00K-$5.00K
Financing cash flow$52.10M$2.21M$381.00K$1.97M$0$14.81M$48.20M$61.90M-$265.00K$305.00K
Net change in cash$33.30M-$12.42M-$14.48M-$11.14M-$12.93M$1.24M$39.00M$52.84M-$8.69M-$9.48M
Stock-based compensation$4.97M$1.91M$4.97M$5.62M$5.19M$5.68M$6.79M$2.98M$2.05M$1.76M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

PULSE BIOSCIENCES, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$18.80M-$14.63M-$14.86M-$13.10M-$12.91M-$13.57M-$9.20M-$9.06M-$8.42M-$9.78M
Gross margin37.1%7.7%1.5%-224.4%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-5823.0%-4775.6%-6914.0%-23682.6%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF margin-4331.6%-3647.9%-5628.8%-15233.7%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue1145.9%476.8%1882.6%6531.4%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio9.63x7.26x10.53x10.02x12.05x15.58x11.88x11.93x4.57x7.06x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net margin-5681.3%Unavailable-6603.4%-22540.7%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenue3911.5%3139.7%4139.0%13247.7%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenue20.7%8.2%39.8%72.1%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable0.0%UnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PLSE in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-02-19View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Reconciliation checks needing review

4 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2023-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-09-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-06-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-03-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.